DOJ Expands Cannabis Schedule III Beyond FDA-Approved Products
Acting AG's final order includes state-licensed medical marijuana, creating broader tax relief than expected for cannabis operators.
The Department of Justice delivered a broader cannabis rescheduling order than industry observers expected, extending Schedule III classification beyond FDA-approved products to include all state-licensed medical marijuana. Acting Attorney General Todd Blanche's directive covers both FDA-approved cannabis drugs and marijuana operating under state medical licensing frameworks, creating immediate tax implications for operators across legal markets.
The expanded scope transforms the financial landscape for medical cannabis companies, which can now access Section 280E tax relief previously unavailable under Schedule I classification. Multi-state operators like Curaleaf Holdings (CURLF), Green Thumb Industries (GTBIF), and Trulieve Cannabis (TCNNF) stand to benefit from deducting standard business expenses including rent, salaries, and marketing costs that federal tax code previously prohibited.
The inclusion of state-licensed programs represents a significant departure from narrow interpretations that would have limited Schedule III benefits to specific FDA-approved products like Epidiolex. This broader framework potentially covers thousands of licensed dispensaries and cultivation facilities operating in the 38 states with medical marijuana programs, creating substantial cost savings that should flow directly to bottom lines.
Tax relief timing remains critical as cannabis companies navigate cash flow challenges and profitability pressures. The rescheduling takes effect immediately, allowing operators to adjust their tax strategies for current fiscal periods. Companies with substantial state-licensed medical operations may see the most dramatic margin improvements, particularly those with significant operational expenses previously non-deductible under 280E restrictions.
The order establishes a framework that could influence future recreational cannabis policy, though adult-use programs remain under Schedule I restrictions. This creates a two-tier system where medical operators gain competitive advantages through improved tax treatment, potentially accelerating the shift toward medical-focused business models among multi-state operators seeking immediate financial benefits from federal rescheduling.